Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, Department of Medicine, McGill University Health Centre, Royal Victoria Hospital, Glen Site - C04.4180, 1001 Boulevard Décarie, Montreal, Quebec H4A 3J1, Canada.
Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
J Clin Lipidol. 2023 Jul-Aug;17(4):452-457. doi: 10.1016/j.jacl.2023.05.093. Epub 2023 May 12.
Because cholesterol-depleted Apo B particles are thought to be a hallmark of hypertriglyceridemia, American, Canadian and European Lipid Guidelines suggest screening for Apo B only in patients with hypertriglyceridemia. Accordingly, this study examines the relationship of triglycerides to the LDL-C/Apo B and non-HDL-C/Apo B ratios.
The study cohort consisted of 6272 NHANES subjects adjusted for a weighted sample size of 150 million subjects without previously diagnosed cardiac disease. Data was reported by LDL-C/Apo B tertiles as weighted frequencies and percent. Sensitivity, specificity, negative predictive and positive predictive values were calculated for triglycerides thresholds of >150 mg/dL and >200 mg/dL. The range of values of Apo B for decisional levels of LDL-C and non-HDL-C were also determined RESULTS: Among patients with triglycerides >200 mg/dL, 75.9% were amongst the lowest LDL-C/Apo B tertile. However, this represents only 7.5% of the total population. Of patients with the lowest LDL-C/Apo B ratio, 59.8% had triglycerides <150 mg/dL. Moreover, there was an inverse relationship between non-HDL-C/Apo B such that elevated triglycerides were associated with the highest tertile of non-HDL-C/Apo B. Finally, the range of values of Apo B for decisional levels of LDL-C and non-HDL-C was determined and is so broad- 30.3-40.6 mg/dl Apo B for different levels of LDL-C and 19.5 to 27.6 mg/dl Apo B for different levels of non-HDL-C- that neither is an adequate clinical surrogate for Apo B.
Plasma triglycerides should not be used to restrict the measurement of Apo B since cholesterol-depleted Apo B particles may be present at any level of triglyceride.
由于载脂蛋白 B 颗粒中的胆固醇含量较低被认为是高甘油三酯血症的标志,美国、加拿大和欧洲的脂质指南建议仅在高甘油三酯血症患者中筛查载脂蛋白 B。因此,本研究探讨了甘油三酯与 LDL-C/载脂蛋白 B 和非 HDL-C/载脂蛋白 B 比值的关系。
研究队列由 6272 名 NHANES 受试者组成,经过加权处理,样本量为 1.5 亿名无先前诊断为心脏病的受试者。报告的数据根据 LDL-C/载脂蛋白 B 三分位数进行加权频率和百分比。计算了甘油三酯阈值>150mg/dL 和>200mg/dL 时的敏感性、特异性、阴性预测值和阳性预测值。还确定了 LDL-C 和非 HDL-C 决策水平的载脂蛋白 B 值范围。
在甘油三酯>200mg/dL 的患者中,75.9%处于 LDL-C/载脂蛋白 B 三分位数最低的范围内。然而,这只占总人口的 7.5%。在 LDL-C/载脂蛋白 B 比值最低的患者中,59.8%的甘油三酯<150mg/dL。此外,非 HDL-C/载脂蛋白 B 之间存在反比关系,即升高的甘油三酯与非 HDL-C/载脂蛋白 B 的最高三分位数相关。最后,确定了 LDL-C 和非 HDL-C 决策水平的载脂蛋白 B 值范围非常广泛——不同 LDL-C 水平的载脂蛋白 B 值范围为 30.3-40.6mg/dl,不同非 HDL-C 水平的载脂蛋白 B 值范围为 19.5-27.6mg/dl——因此,两者都不能作为载脂蛋白 B 的充分临床替代物。
由于载脂蛋白 B 颗粒中的胆固醇含量较低可能存在于任何水平的甘油三酯中,因此不应使用血浆甘油三酯来限制载脂蛋白 B 的测量。